A health ministry panel decided Friday to designate the sedative thalidomide as a priority research drug for bone marrow cancer treatment, more than 40 years after it was banned for causing severe birth defects.
Osaka-based Fujimoto Pharmaceutical Corp. filed a request last year for the ministry to designate thalidomide as what is technically known as an "orphan drug."
Under the ministry's definition, an orphan drug is a product used to treat rare but serious diseases that affect fewer than 50,000 patients. Any manufacturer of such a drug receives official backing in research and development, extended market monopoly status and tax breaks.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.